Structures of Pathogenic Fungal FKBP12s Reveal Possible Self-Catalysis Function

Nam K. Tonthat, Praveen Rao Juvvadi, Hengshan Zhang, Soo Chan Lee, Ron Venters, Leonard Spicer, William J. Steinbach, Joseph Heitman, Maria A. Schumacher

ABSTRACT  Invasive fungal infections remain difficult to treat and require novel targeting strategies. The 12-kDa FK506-binding protein (FKBP12) is a ubiquitously expressed peptidyl-prolyl isomerase with considerable homology between fungal pathogens and is thus a prime candidate for future targeting efforts to generate a panfungal strategy. Despite decades of research on FKBPs, their substrates and mechanisms of action remain unclear. Here we describe structural, biochemical, and in vivo analyses of FKBP12s from the pathogenic fungi Candida albicans, Candida glabrata, and Aspergillus fumigatus. Strikingly, multiple apo A. fumigatus and C. albicans FKBP12 crystal structures revealed a symmetric, intermolecular interaction involving the deep insertion of an active-site loop proline into the active-site pocket of an adjacent subunit. Such interactions have not been observed in previous FKBP structures. This finding indicates the possibility that this is a self-substrate interaction unique to the A. fumigatus and C. albicans fungal proteins that contain this central proline. Structures obtained with the proline in the cis and trans states provide more data in support of self-catalysis. Moreover, cysteine cross-linking experiments captured the interacting dimer, supporting the idea that it forms in solution. Finally, genetic studies exploring the impact of mutations altering the central proline and an adjacent residue provide evidence that any dimeric state formed in vivo, where FKBP12 concentrations are low, is transient. Taken together, these findings suggest a unique mechanism of self-substrate regulation by fungal FKBP12s, lending further novel understanding of this protein for future drug-targeting efforts.

IMPORTANCE  FKBP12 is a cis-trans peptidyl-prolyl isomerase that plays key roles in cellular protein homeostasis. FKBP12s also bind the immunosuppressive drug FK506 to inhibit the phosphatase calcineurin (CaN). CaN is required for virulence of A. fumigatus, C. albicans, C. glabrata, and other deadly fungal pathogens, marking FKBP12 and CaN as potential broad-spectrum drug targets. Here we describe structures of fungal FKBP12s. Multiple apo A. fumigatus and C. albicans FKBP12 structures reveal the insertion of a proline, conspicuously conserved in these proteins, into the active sites of adjacent molecules. This suggests that these proteins might serve as their own substrates. Cysteine disulfide trapping experiments provide support for this self-interaction and hence possible intermolecular catalysis by these enzymes.
identical interacting regions in the catalytic and regulatory domains of CaN proteins. Hence, fungal FKBP12s have emerged as potential targets for the development of broadly acting antifungal agents (21). The development of novel antifungal agents that specifically target the FKBP12 component in this pathway would be significantly aided by the structural elucidation of these proteins.

While there are currently no structures available for the fungal pathogen FKBP12s, multiple structures of FKBP12 and highermolecular-weight FKBP1s from humans and other organisms (including the model yeast *Saccharomyces cerevisiae*) have been determined in both their apo states and in complex with FK506 and rapamycin (27, 33, 34). These structures reveal that the FKBP1s share the same overall fold that includes a five- to six-stranded β-sheet that wraps around an α-helix. Three extended loops, which have been called the 40s loop (between β2 and β3), the 50s loop (between β3 and α1), and the 80s loop (between β4 and β5), surround a deep active-site pocket that binds both FK506 and rapamycin (18, 19). Despite the numerous structural, biochemical, and in vivo studies of FKBP1s that have been carried out, their substrate specificities and catalytic mechanisms are still unclear. Indeed, there are no structures available for an FKBP12-substrate complex. The only structure that gives some insight into this enzyme-substrate interaction is the structure of the FKBP domain from *Plasmodium vivax* FKBP35 (PvFKBP35) in complex with the unnatural tetrapeptide substrate succinyl-Ala–Leu–Pro–Phe–p-nitroanilide (35). However, the physiological relevance of this structure is unclear, as data showed that PvFKBP35 is a monomer and in the crystal structure the substrate peptide is bound between two subunits of a crystallographic dimer.

To gain insight into the structure and function of the FKBP12s of *C. albicans*, *C. glabrata*, and *A. fumigatus*, we performed structural, biochemical, and genetic studies. Strikingly, the *C. albicans* and *A. fumigatus* FKBP12 apo structures all revealed the deep insertion of a proline located in the 80s loop into the ligand-binding pocket of a neighboring FKBP12 subunit. This interaction was not observed in the *C. glabrata* structure, which does not have the corresponding proline residue. Comparison of the apo structures with FKBP12-FK506 complexes reveals that this “self-substrate” overlaps the binding site of FK506. As FK506 is a transition state analog, these data suggest the possibility that these fungal FKBP12s might function as their own substrates. To test this hypothesis, we generated a single-cysteine mutant that was able to trap the self-interacting dimer, showing that it forms in solution. We also performed genetic studies to probe the effects of mutations in the 80s loop of *A. fumigatus* FKBP12. The combined studies support the possibility that the *A. fumigatus* and *C. albicans* FKBP12s may function as their own substrates, lending unique insight into this conserved and targetable fungal protein.

### RESULTS

Structures of the apo *A. fumigatus* and *C. albicans* FKBP12s.

The *C. albicans* and *A. fumigatus* FKBP12s represent potential drug targets in treating invasive fungal infections. To gain insight into the structures and functions of these proteins, we determined their crystal structures. Three different crystal forms of the apo *C. albicans* FKBP12, to resolutions of 1.99, 2.3, and 2.4 Å, were obtained (Table 1). The FKBP12 subunit structures of the three crystal forms are essentially identical (root mean square deviations [RMSDs] of ~0.2 to 0.4 Å for superimpositions of corresponding C-α atoms) (Fig. 1A and B). Structural homology searches with DALI revealed that the *C. albicans* apo FKBP12 structures show significant structural homology to all FKBP12s, with the strongest similarity to the human protein (Protein Data Bank [PDB] code 1d7h); superimposition of corresponding C-α atoms of the *C. albicans* and human FKBP12 structures resulted in an RMSD of 1.02 Å (Fig. 1C). Like other FKBP12 structures, the *C. albicans* protein harbors the typical core FKBP12 structure, which consists of a five-stranded β-sheet wrapped about the central helix. In addition, *C. albicans* FKBP12 has an insert of 12 residues between α1 and β4 (Fig. 1A and C). Despite the extra residues in the insert region of the *C. albicans* structure, it contains the same pocket as other FKBP1s, which is framed by the 40s, 50s, and 80s loops (Fig. 1C).

### Table 1. Data collection and refinement statistics for *C. albicans* FKBP12 structures

| Parameter               | C. albicans FKBP12 apo form: | Apo C. albicans FKBP12(FK506) | Apo C. albicans FKBP12(FK506) |
|-------------------------|------------------------------|-------------------------------|-------------------------------|
|                         | 1                            | 2                            | 3                            |
| Space group             | C2                           | P2,2,2                        | P1                           |
| Unit cell dimensions    | a, b, c (Å)                  | α = β = γ (°)                 | Resolution (Å)               |
|                         | 99.6, 43.0, 70.7             | 35.8, 80.7, 94.9              | 26.0–2.4                     |
| Resolution (Å)          | 10.1 (19.7)°                 | 9.1 (31.2)°                  | 26.1–2.9                     |
| Rmerge (%)              | 3.6 (55.9)°                  | 5.8 (2.0)°                   | 25.96–2.4                    |
| Completeness (%)        | 23.6 (2.0)°                  | 85.2 (38.5)°                 | 40.9–2.3                     |
| Redundancy              | 2.3 (2.4)°                   | 1.6 (1.6)°                   | 63.8–1.99                    |
| Refinement              | 25.96–2.4                    | 6.4 (55.9)°                  | 26.1–2.9                     |
| Resolution range (Å)    | 17.7/22.2°                   | 22.5/25.4°                   | 10.1 (19.7)/13.2 (6.3)       |
| No. of atoms            | 1,733                        | 1,808                        | 17.7/22.2°                   |
| Protein                 | 129                          | 67                           | 1,733                        |
| Water                   | 67                           | 166                          | 1,808                        |
| RMSD                    | 0.004                        | 0.008                        | 0.004                        |
| Bond length (Å)         | 1.42                         | 1.29                         | 0.002                        |
| Bond angle (°)          | 0.86                         | 0.88                         | 0.008                        |

* Values in parentheses are for the highest-resolution shell.
C. albicans apo FKBP12 structures reveal intermolecular contacts between active sites. While the C. albicans apo FKBP12 structure is very similar to previously determined FKBP12 structures, an unexpected finding that emerged from analysis of the crystal packing was that despite being obtained under very different crystallization conditions with distinct crystal lattices, all three C. albicans apo FKBP12 structures displayed the same intermolecular interactions between subunits (Fig. 2A). What is notable about this interaction is that the 80s loop of one subunit docks into the active site of the adjacent subunit and vice versa, suggesting that the loop may act as a substrate. Indeed, Pro104, which is located at the tip of the loop and shown as a CPK model, is the most deeply inserted side chain, and it contacts key residues shown to be important for FKBP12 PPIase activity. Notably, the Asp41 side chain makes hydrogen bonds with the Pro104 carbonyl oxygen in each pocket.

C. albicans apo FKBP12 structures displayed the same intermolecular interactions between subunits (Fig. 2A). What is notable about this interaction is that the 80s loop of one subunit docks into the active site of the adjacent subunit and vice versa, suggesting that the loop may act as a substrate. Indeed, Pro104, which is located at the tip of the loop, is inserted most deeply into the active site of the adjacent subunit.
pocket and is surrounded by residues that have been implicated, via mutagenesis, to be involved in FKBP PPIase activity (36, 37). Three residues, in particular, were implicated as important for FKBP12 catalysis and correspond to Val59, Asp41, and Tyr97 in the C. albicans protein (Fig. 2B). These residues all make direct contacts with Pro104, which rests within an aromatic cleft formed by Tyr30, Phe50, and Trp63 (Fig. 2B). Notably, the interface in the C. albicans FKBP12-FKBP12 interaction is minimal (burying 592 Å² from solvent), which suggests that, like known substrate-enzyme complexes, the proteins form a weak interaction; typical dimer interfaces bury >2,000 Å² of surface from solvent. Although most of the contacts that hold the loop in position in the active site are with the central Pro104, additional hydrophobic contacts with Ile102, Pro103, and Ile105 are provided, while Arg100 makes hydrogen bonds with the carbonyl oxygens at the edge of the pocket.

Studies have indicated that the immunosuppressant FK506 functions as a transition state mimic when bound to FKBP (19). Comparison of the C. albicans FKBP12 apo structure with FKBP12-FK506 structures reveals that the 80s loop binds in the same pocket as FK506. However, to confirm that this is indeed the catalytic pocket in the C. albicans protein, we next sought to determine the C. albicans FKBP12-FK506 structure. Interestingly, initial attempts to obtain crystals of the protein-FK506 complex failed, as the intermolecular interaction appeared to be strongly favored, leading to the production of the same apo crystal forms. Thus, we generated a P104G mutation in C. albicans FKBP12 and crystallized and obtained the apo FKBP12(P104G) structure to 2.0 Å (Table 1). Strikingly, this structure did not harbor the self-catalysis-like interaction (see Fig. S1 in the supplemental material). We next used the FKBP12(P104G) protein to obtain the structure bound to FK506 (Table 1). The structure revealed that, similar to other FKBP12-FK506 complexes, the immunosuppressant binds in the active-site pocket, surrounded by the 40s, 50s, and 80s loops. Comparison of this structure with the apo C. albicans structures with bound self-substrates revealed that the 80s loop that is inserted into the active site of the adjacent subunit binds in precisely the same location as the FK506 substrate/transition state homolog (Fig. 3).

A. fumigatus FKBP12 structures: self-catalysis captured? Our data thus far revealed that C. albicans FKBP12 contains a proline residue at the tip of its 80s loop, Pro104, that, in the apo form, is inserted into the active site of a neighboring subunit. Sequence alignments revealed that A. fumigatus FKBP12 contains the same proline residue in its 80s loop that makes intermolecular interactions in the C. albicans protein (Table 2; Fig. 4A). Thus, to deduce if A. fumigatus FKBP12 might form a similar self-substrate-like interaction, we crystallized and determined the structure of the apo form of the protein. Remarkably, we observed the same insertion of the 80s loop of each subunit into the active site of the other subunit (Fig. 4B). As for C. albicans FKBP12, we also had difficulty obtaining the structure of the A. fumigatus wild-type (WT) protein in complex with FK506. Thus, we generated the analogous mutation, P90G, and used that protein to obtain the FKBP12(P90G)-FK506 structure. As expected the FK506 molecule is bound in the same active-site pocket of A. fumigatus FKBP12 as in other FKBP12-FK506 complex structures (Fig. 4C). Interestingly, unlike the C. albicans apo FKBP12 structures, which were all captured with Pro104 in the cis conformation, in the A. fumigatus structure, Pro90 in one subunit was bound in the cis conformation and Pro90 in the other was bound in the trans state, thus potentially providing a snapshot of self-catalysis (Fig. 4B).

C. glabrata FKBP12 structures. Sequence alignments of FKBP12s from various fungal pathogens revealed that only the A. fumigatus and C. albicans proteins contain a central proline in the 80s loop. Another clinically important and often antifungal-resistant Candida species, C. glabrata, contains a glycine at this location, suggesting that this protein would not form the intermolecular interaction. To test this prediction, we determined the structures of C. glabrata FKBP12 in its apo and FK506-bound states (Table 3). Examination of the packing revealed a close contact between the 80s loop of one subunit and an adjacent molecule in the apo crystals. However, here the 80s loop is not inserted into the active site of the neighboring molecule. Hence, as predicted, the C. glabrata FKBP12 structure shows no evidence of an intermolecular self-catalysis-like binding event (see Fig. S2 in the supplemental material). However, to ensure that it utilizes the same active site, we obtained the structure in the presence of FK506 to 1.3 Å. As this structure clearly shows, FK506 binds to the active-site pocket by using a binding mode identical to that used by C. albicans, A. fumigatus, and other FKBP12s, including human FKBP12 (Fig. 4C).

Disulfide cross-linking captures the FKBP12 intermolecular interaction. While every structure of the WT apo A. fumigatus and C. albicans FKBP12s revealed the same interproline interaction, even under very diverse crystallization conditions, it remained possible that these were all crystallization artifacts. Thus, to assess if this interaction occurs in solution, we made a single cysteine mutation, V91C, in the A. fumigatus protein to try to capture a disulfide cross-linked complex. This residue was chosen for mutation because the structure revealed that the V91 and V91′ (where the prime indicates the other subunit of the dimer) side chains are within <4.0 Å of each other and that when they are mutated to cysteines in silico they could form a disulfide bond in the intermolecular dimer. The A. fumigatus FKBP12(V91C) mutant was expressed in two Escherichia coli cell lines, C41(DE3) and SHuffle cells (see Materials and Methods). SHuffle cells constitu-
tively express a chromosomal copy of the disulfide bond isomerase DsbC, which promotes disulfide bond formation in the cytoplasm. When the proteins were purified from both strains in the absence of a reducing agent and subjected to nonreducing SDS-PAGE, the samples revealed the presence of two species, which were consistent with FKBP12 monomers and dimers (Fig. 5A). While the protein was not as well expressed in SHuffle cells, the samples purified from these cells ran primarily as dimers. When a reducing agent (β-mercaptoethanol) was added, the proteins ran as monomers (Fig. 5A). However, to ensure that the dimeric species in the gel was not an impurity that was sensitive to the reducing agent, we performed mass spectrometry of the dimer and monomer bands. The results confirmed that both species contained the A. fumigatus FKBP12(V91C) protein (data not shown).

We next separated the V91C dimer from the monomer via size exclusion chromatography and crystallized and solved the structure of the dimer to 3.2 Å resolution. The structure revealed a disulfide cross-linked dimer. Interestingly, although revealing the same general dimer that we observed in the A. fumigatus and C. albicans apo FKBP12 structures, in the FKBP12(V91C) structure (Fig. 5B), Pro90 is slightly shifted from the active site and adopts a twisted conformation (Fig. 5C and D), suggesting that the structure may have captured an intermediate state of catalysis. In fact, the conformation of the Pro90 residues in the structure is closer to the trans than the cis state and overlays of the trans state of the protein to form an all-trans dimer revealed a clash. This finding suggests the intriguing possibility that part of the mechanism of prolyl isomerization by FKBP5s is dictated by the conformation of the substrate during catalysis. Indeed, the cis and trans states lead to structural changes in the loops and one state may be more occupied in the cell compared to that used for crystallization. Indeed, enzyme-substrate interactions cannot be tight, as that would prevent product turnover.

Interestingly, we did observe that there is potential variation in the interaction affinity between FKBP12 and its variants during control interactions with the FKBP12-rapamycin complex-binding (FRB) domain of the TOR protein. Specifically, when the N terminus of FKBP12 or FKBP12(V91C) was linked with the AD (AD-FkbA or AD-FkbA(V91C)), it did not interact with the FRB domain in the presence of rapamycin, in contrast to other fungal FKBP12s, which revealed a strong interaction with the FRB domain under these conditions (39, 40). On the other hand, A. fumigatus AD-FKB12(P90G) did reveal an interaction with the FRB domain in the presence of rapamycin. These data suggest that the FKBP12s, which revealed a strong interaction with the FRB domain in the presence of rapamycin, in contrast to other fungal FKBP12s, which revealed a strong interaction with the FRB domain under these conditions (39, 40). On the other hand, A. fumigatus AD-FKB12(P90G) did reveal an interaction with the FRB domain in the presence of rapamycin. These data suggest that the properties of A. fumigatus FKBP12 may be altered by changing the amino acid at the 90th residue from proline to glycine.

We do not think that the failure to observe AD-FkbA or AD-FkbA(V91C) binding to the FRB domain is due to complete occupation of the AD-FkbA active site by another AD-FkbA molecule forming the dimer, as we expect this type of self-interaction to be transient. Similarly, because the cytoplasm and nucleus are reducing environments, we do not think the FkbA(V91C) disulfide-linked dimer will be a predominant species under these conditions.
It is possible that the conformation of the 80s loop in WT FkbA (or V91C) versus FkbA(P90G) influences the binding of the FKBP12-rapamycin complex to the FRB domain of the TOR protein.

A. fumigatus FKBP12(P90G) and FKBP12(V91C) mutations confer FK506 resistance. On the basis of our structural and biochemical studies, the FKBP12(P90G) mutant would be predicted to be unable to self-catalyze, while the FKBP12(V91C) mutant might have altered target-binding properties. To test this, A. fumigatus strains expressing FKBP12(P90G) and FKBP12(V91C) tagged with enhanced green fluorescent protein (EGFP) were generated and assessed for susceptibility to FK506 treatment. As shown in Fig. 6A, both of the mutations induced relative FK506 resistance. FKBP12(V91C) exhibited greater resistance to FK506 than FKBP12(P90G) did (Fig. 6A; see Fig. S4 in the supplemental material), indicating a potential loss of affinity for CaN. In order to examine the binding of the mutated FKBP12s to CaN, we also screened for their intracellular localization in the absence or presence of FK506. In the absence of FK506, FKBP12(P90G) and FKBP12(V91C) localized evenly throughout the cytoplasm and also in the nuclei (Fig. 6B). Upon exposure to FK506, septal localization in a disc-like pattern, as noted earlier with CaN, was evident (Fig. 6B). Interestingly, however, both the FKBP12(P90G) and FKBP12(V91C) proteins were still able to bind to CaN at the septa but to a lesser extent than WT FKBP12. Furthermore, FKBP12(V91C) showed 40 to 50% less septal localization than WT FKBP12, confirming its lower affinity for CaN. These observations support the idea that the sequence and conformation of the 80s loop can influence fungal FKBP12-FK506 binding to CaN, in accordance with previous studies of human FKBP12-FK506 binding to CaN (41).

**FIG 4** Alignment of FKBP12 sequences. The 80s loop proline is conserved in C. albicans and A. fumigatus FKBP12 but not in C. glabrata, and H. sapiens FKBP12s. (A) Sequence alignments of the FKBP12s of C. albicans, A. fumigatus, C. glabrata, and H. sapiens. Secondary structural elements are shown above the sequence. Identical and highly conserved residues are highlighted in cyan and yellow, respectively. (B) The A. fumigatus FKBP12 apo structure shows the same self-interaction as C. albicans FKBP12. Shown side by side are the self-interacting dimers of A. fumigatus and C. albicans. The proline corresponding to C. albicans Pro104 is Pro90 in A. fumigatus FKBP12, and interestingly, the A. fumigatus structure shows one subunit with Pro90 in the cis conformation and one with Pro90 in the trans conformation. (C) Superimpositions of the FKBP12-FK506 structures of H. sapiens, C. albicans, C. glabrata, and A. fumigatus, all showing the identical mode of FK506 binding.
TABLE 3 Data collection and refinement statistics for *C. glabrata* FKBP12 structures

| Parameter               | Apo *C. glabrata* FKBP12 | *C. glabrata* FKBP12-FK506 |
|-------------------------|--------------------------|---------------------------|
| Space group             | 1422                     | P6_3                      |
| Cell dimensions         | 76.4, 76.4, 87.0          | 77.8, 77.8, 53.6          |
| α, β, γ (°)             | 90.0, 90.0, 90.0          | 90.0, 90.0, 90.0          |
| Resolution (Å)          | 43.5–2.65                | 42.0–1.30                 |
| Rmerge (%)              | 12.0 (36.6)              | 4.6 (41.4)                |
| R(ref) (%)              | 11.8 (2.8)               | 11.7 (1.7)                |
| Completeness (%)        | 98.7 (47.3)              | 97.7 (93.3)               |
| Redundancy              | 3.3 (2.2)                | 3.6 (2.0)                 |
| Refinement              |                          |                           |
| Resolution (Å)          | 43.5–2.65                | 42.0–1.30                 |
| Rmerge / Rwork (%)      | 21.4/26.0                | 15.3/16.4                 |
| No. of atoms            | 873                      | 873                       |
| Protein                 | 17                       | 246                       |
| Water                   | 0.003                    | 0.025                     |
| Bond length (Å)         | 0.73                     | 2.14                      |

*Values in parentheses are for the highest-resolution shell.*

**DISCUSSION**

The FKBP12s of the pathogenic fungi *A. fumigatus*, *C. albicans*, and *C. glabrata* have emerged as potential targets for drug design because of their role in the inhibition of CaN, a critical component of a cell signaling pathway essential for fungal pathogenesis (31). FKBP12 inhibits CaN by binding the immunosuppressant FK506. This FKBP12-FK506 complex then docks onto CaN, preventing it from binding substrates. Hence, the design of fungus-specific inhibitors of this complex would be greatly aided by structures of fungal FKBP12s in the presence or absence of FK506 and FK506-like compounds. Therefore, we undertook the determination of the structures of the *A. fumigatus*, *C. albicans*, and *C. glabrata* FKBP12s in their apo and FK506-bound forms. The apo structures of the *A. fumigatus* and *C. albicans* proteins all revealed the unexpected finding that one of the loops, the 80s loop, is inserted into the active-site pocket of an adjacent subunit. This finding led to the hypothesis that the *A. fumigatus* and *C. albicans* FKBP12s may function to isomerize their own proline residues. Support for this notion comes from previous mutagenesis studies (36) that revealed that the central hydrophobic pocket where the prolines from the 80s loop bind is indeed the location of the PPIase active site. However, despite the large number of FKBP structures solved to date, no structure of an FKBP bound to a substrate is currently available, which has left the details of the PPIase mechanism unclear and has limited structure-based targeting design efforts. Thus, if the *A. fumigatus* and *C. albicans* FKBP12 apo structures have captured a self-substrate interaction, this would be significant, as it would indicate that these represent the first FKBP-substrate complex structures. Support for this hypothesis was provided by the analysis of a cysteine mutant form of the *A. fumigatus* protein that trapped the interacting dimer.

The possibility that the 80s loop of the fungal proteins might function as a self-substrate would be of interest from a physiological standpoint, as studies have highlighted the 80s loop as a key region in the interactions of FKBP12s with other proteins (26). As *cis/trans* isomerization impacts the conformation of this loop, it would significantly affect the functions of FKBP12 outside their PPIase activity. Indeed, FKBP1s, which are ubiquitous molecules with homologs found in bacteria to higher eukaryotes, carry out a wide range of functions, including roles outside their PPIase activity (26). For example, studies with mice revealed that FKBP12 is critical for modulating the calcium release activity of both skeletal and cardiac ryanodine receptors (42). FKBP12 was also shown to be a regulator of the cell cycle through its effect on transforming growth factor beta receptor signaling (20). However, the specific functions of FKBP12 appear to vary dramatically between organisms. This diversity of FKBP functions has made analyzing the contributions of PPIase activity versus effector protein binding difficult and also indicates that the role of FKBP12 in each organism must be dissected individually. In this regard, it is currently not possible to obtain a clear genetic assessment of the hypothesis that the *A. fumigatus* and *C. albicans* FKBP12s act as their own substrates because the cellular roles of these proteins in these fungi have yet to be elucidated. Therefore, further studies are needed to deduce the potential importance of *A. fumigatus* and *C. albicans* FKBP12 self-catalysis and its possible effects on isomerization targets and interacting proteins and their impacts on resultant cellular pathways.

**MATERIALS AND METHODS**

Protein expression and purification. Genes encoding the *C. albicans* and *A. fumigatus* FKBP12s that were codon optimized for *E. coli* expression were purchased from the GenScript Corporation (Piscataway, NJ) and subcloned into pET15b such that a hexahistidine tag (His tag), cleavable by thrombin, was added to the N termini. The proteins were expressed in *E. coli* BL21(DE3) cells. For protein expression, cells were grown to an optical density at 600 nm of ~0.6 at 37°C. At that time, the temperature was reduced to 15°C and isopropyl-β-D-thiogalactopyranoside was added to a final concentration of 1 mM. The cultures were allowed to grow for an additional 14 to 16 h, and the cells were pelleted and lysed in purification buffer (300 mM NaCl, 20 mM Tris-HCl [pH 7.5], 20 mM imidazole). The proteins were purified from the soluble fraction of the lysate via nickel-nitrilotriacetic acid (NTA) chromatography. Fractions containing FKBP12 were pooled and treated with thrombin at 4°C for 14 to 16 h to remove the N-terminal His tag. The digested sample was then applied to an Ni-NTA column, and the flowthrough was collected and loaded onto a Superdex 75 size exclusion column (GE Healthcare) equilibrated in elution buffer (150 mM NaCl, 20 mM Tris-HCl [pH 7.5]). The fractions containing pure protein were pooled and concentrated for biochemical studies and crystallization.

Crystallization and determination of the structures of *A. fumigatus* and *C. albicans* FKBP12 apo and FK506 complexes. *C. albicans* FKBP12 was crystallized in three different space groups, P1, P2_12_1, and C2, by hanging-drop vapor diffusion. The P1 crystal form was obtained by using a mixture of 25% polyethylene glycol (PEG) 3000, 0.1 M NaCl, and 0.1 M Tris-HCl (pH 8.0) as a crystallization reagent. The P2_12_1 form grew in a solution of 2 M ammonium sulfate and 0.1 M citrate (pH 5.5), and the C2 crystal form was crystallized in a mixture of 25% PEG 8000, 0.1 M sodium acetate (pH 4.5), and 0.2 M lithium sulfate. Each hanging drop contained a 1:1 ratio of ~10 mg/ml protein to crystallization reagent. The crystallization reagent supplemented with 25% glycerol was used as a cryosolvent. For cryopreservation, the crystals were dipped for several seconds in the cryosolvent prior to their placement in the liquid nitrogen stream. The *C. albicans* FKBP12(F104G)-FK506 complex crystallized in the P2_1 space group, in a mixture of 2 M ammonium sulfate, 0.1 M N-cyclohexyl-3-aminopropanesulfonic acid (CAPS)-NaOH (pH 10.5), and 0.2 M lithium sulfate. One millimole of FK506 was added to the protein prior to crystallization. A solution of 4 M ammonium sulfate was used as a cryoprotectant. *A. fumigatus* FKBP12 at a concentration of 20 mg/ml was crystallized in the P2_12_1 space group in a mixture of 2 M ammonium sulfate, 0.1 M Tris-HCl (pH 7.0), and 0.2 M lithium sulfate. A 4 M ammonium sulfate solution was used as a cryoprotectant. *A. fumigatus* FKBP12(P90G)-FK506 crystals were obtained by mixing 20 mg/ml pro-
tein (with 1 mM FK506) with a solution containing 2 M lithium sulfate, 0.1 M Tris-HCl (pH 8.5), and 2% PEG 400 at a 1:1 ratio.

C. albicans FKBP12(P104G) apo crystals were grown by mixing protein at 10 mg/ml 1:1 with a combination of 2 M ammonium sulfate, 0.1 M CAPS (pH 10.5), and 0.2 M lithium sulfate. The crystals could be cryopreserved straight from the drop. Data were collected at Advanced Light Source beamline 8.3.1 or Advanced Photon Source. Data were processed with HKL3000 or MOSFLM. Initial phases were obtained in each case by using molecular replacement (MolRep), starting with the human FKBP12 model (PDB code 2PPN). The A. fumigatus and C. glabrata apo structures were solved by using the C. albicans apo high-resolution structure as a starting model in MolRep. The FK506-bound structures were solved by using the required apo structures as starting models. All model building was carried out with COOT or O, and refinements were performed in PHENIX (42).

Mutant A. fumigatus FKBP12(V91C) construction, disulfide cross-linking experiments, and determination of the structure of the cross-linked dimer. Mutant A. fumigatus FKBP12(V91C) was made with the QuickChange kit. The pET15b plasmid expressing the mutant protein was transformed into C41(DE3) and SHuffle cells. The protein was expressed and purified in the same way as WT A. fumigatus FKBP12, except that no reducing agent was added at any step. The A. fumigatus FKBP12(V91C) dimer was separated from the monomer via size exclusion chromatography, and the His tag was cleaved before crystallization trials. The protein was concentrated to 30 mg/ml, and crystals were grown by mixing the protein solution 1:1 with a reservoir consisting of 1.5 M sodium citrate and 0.1 M sodium cacodylate (pH 6.5). Crystals grew within 3 h and were cryopreserved by being dipped for 1 s in a drop containing the crystallization solution supplemented with 25% glycerol. Data were collected and processed with MOSFLM. The structure was solved by MolRep with the A. fumigatus apo structure as a search model. The structure was refined with PHENIX (43).

Construction of A. fumigatus FKBP12(P90G) and FKBP12(V91C) strains. A. fumigatus WT strain akuBKU80 was used for all transformation experiments and grown on glucose minimal medium (GMM) at 37°C.
TABLE 4 Interactions of FKBP12, FKBP12 variants, and the FRB domain determined by Y2H analysis

| AD-gene fusion | BD-gene fusion | Interaction | Drug |
|----------------|----------------|-------------|------|
| FKBP12         | FRB            | –           | Rapamycin |
| FKBP12         | FRB            | +           | Rapamycin |
| FKBP12(P90G)   | FRB            | –           | Rapamycin |
| FKBP12(V91C)   | FRB            | –           | Rapamycin |
| FKBP12(P90G)   | FKBP12         | +           | Rapamycin |
| FKBP12(V91C)   | FKBP12         | –           | Rapamycin |
| FKBP12(P90G)   | FKBP12(V91C)   | –           | Rapamycin |
| FKBP12(V91C)   | FKBP12(P90G)   | –           | Rapamycin |
| FKBP12         | FKBP12(P90G)   | –           | Rapamycin |
| FKBP12         | FKBP12(V91C)   | –           | Rapamycin |
| FKBP12(P90G)   | FKBP12(V91C)   | –           | Rapamycin |
| FKBP12(V91C)   | FKBP12(P90G)   | –           | Rapamycin |

a N termini of FKBP12s were fused with the GAL4 AD.

b Both rapamycin and FK506 were used at 1 μg/ml.

c C termini of FKBP12s were fused with the GAL4 AD.

FIG 6 In vivo analysis of mutant A. fumigatus FKBP12s. (A) Radial growth of the WT strain (akuBku80) and the strains expressing WT FKBP12-GFP and the mutated versions of FKBP12 [FKBP12(P90G) and FKBP12(V91C)] tagged with GFP were assessed after 5 days on GMM agar with or without supplementation with FK506 (100 ng/ml). Note the resistance of the FKBP12(P90G)- and FKBP12(V91C)-producing strains to FK506. (B) Strains expressing WT FKBP12-GFP and the mutated versions of FKBP12 [FKBP12(P90G) and FKBP12(V91C)] tagged with GFP were cultured in liquid GMM in the absence or presence of FK506 (100 ng/ml) on coverslips for 18 to 20 h and observed for the localization of FKBP12 by fluorescence microscopy. Note the complete cytosolic localization of FKBP12s in the absence of FK506. Arrows indicate the translocation of FKBP12s to the hyphal septa in the presence of FK506 indicative of their binding to CaN at the hyphal septa. Scale bar, 10 μm. (C) Western analysis performed with the anti-GFP polyclonal primary antibody and a peroxidase-labeled anti-rabbit IgG secondary antibody. The arrow indicates the ~37-kDa FKBP12-GFP fusion protein. The values on the left are molecular masses in kilodaltons.

(44). In certain experiments, GMM agar or RPMI liquid medium was supplemented with FK506 (0.1 to 10 μg/ml). All radial-growth experiments were repeated three times, each in triplicate. E. coli DH5α competent cells were used for subcloning. Site-directed mutagenesis of two FKBP12 residues (P90G and V91C) was performed with the primers listed in Table S2 in the supplemental material and the pUCGH-FKBP12 plasmid (45), consisting of 384 bp of the 637-bp fkbp12 gene (fkbp12/Afu6g12170, http://www.aspergillusgenome.org) and ~1 kb of the fkbp12 terminator sequence as the template. Briefly, in the first PCR, two fragments were amplified with complementary primers (with respective mutations) overlapping the fkbp12 region to be mutated and the respective primers at the N and C termini of fkbp12. No stop codon was introduced at the C-terminal end of fkbp12 to facilitate expression of the gfp fusion. Next, fusion PCR was done with equiproportional mixtures of the two PCR fragments as the templates, and the final mutated 384-bp fkbp12 PCR fragment was amplified with primers at the N and C termini of fkbp12 (see Table S2 in the supplemental material). Mutated fkbp12 fragments were digested with KpnI and BamH1 and cloned into the pUCGH-FKBP12 plasmid by replacing the 384-bp WT fkbp12 PCR fragment to facilitate homologous integration. Mutated fkbp12 genes were sequenced (see Table S2 for the primers used) to confirm the mutation and linearized with KpnI for homologous integration. Linearized constructs were transformed into A. fumigatus akuBku80, and transformants were selected with hygromycin B (150 μg/ml) as previously described (46). Transformants were verified for homologous integration by PCR (see Table S2 and Fig. S5 in the supplemental material) and verified for accuracy of mutation by sequencing and fluorescence microscopy.

Protein extraction and Western analysis. A. fumigatus recombinant strains expressing respective WT and mutated forms of FKBP12-GFP fusion proteins were cultured in liquid GMM at 200 rpm for 24 h at 37°C. Crude extracts were prepared as previously described (47). Approximately 50 μg of protein electrophoresed on a 4 to 20% SDS-polyacrylamide gel was transferred onto a polyvinylidene difluoride
membrane (Bio-Rad) and probed with a rabbit polyclonal antibody. The anti-GFP primary antibody (1 μg/ml; GenScript) and peroxidase-labeled rabbit anti-IgG (1:5,000; Rockland) secondary antibody. Detection was performed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).

**Microscopy.** Conidia (10⁴) from the recombinant strains of *A. fumigatus* were inoculated into 5 ml of GMM, poured over a sterile coverslip (22 by 60 mm; no. 1), and placed in a sterile dish (60 by 15 mm). Cultures grown for 18 to 20 h at 37°C were observed by fluorescence microscopy with an AxioSkop 2 plus microscope (Zeiss) equipped with AxioVision 4.6 imaging software.

**RESULTS**

**Infectious Diseases (NIAID) (AI112595).** This work was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (AI112595). FUNDING INFORMATION

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.00492-16/-/DCSupplemental.

**Figure S1, TIF file, 0.3 MB.**

**Figure S2, TIF file, 0.5 MB.**

**Figure S3, TIF file, 0.2 MB.**

**Figure S4, TIF file, 0.8 MB.**

**Figure S5, TIF file, 0.3 MB.**

**Table S1, DOC file, 0.1 MB.**

**Figure S2, TIF file, 0.5 MB.**

**Table S2, DOC file, 0.03 MB.**

**ACKNOWLEDGMENTS**

Beanline 8.3.1 at the Advanced Light Source is operated by the University of California Office of the President, Multicampus Research Programs and Initiatives, and the University of California Office of the President, Multicampus Research Programs and Initiatives, through a Breakthrough Biomedical Research, which is partially funded by the Sandler Foundation. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by the Argonne National Laboratory under contract DE-AC02-06CH11357. This work was supported by NIH/NI-AID multi-PI R01 award AI112595 and P01 award AO104533 to J.H., L.S., W.S., and M.A.S. J.H. also received support from NIH/NIAID R43 SBIR grant R43 AI098300-01 and an Astellas Pharma Global Development Research grant.

**FUNDING INFORMATION**

This work was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (AI112595). This work was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (AI104533).

**REFERENCES**

1. Brandts JF, Halvorson HR, Brennan M. 1975. Consideration of the possibility that the slow step in protein denaturation reactions is due to cis-trans isomerisation of proline residues. Biochemistry 14:4953–4963. http://dx.doi.org/10.1021/bi00693a026.

2. Schmid FX, Baldwin RL. 1978. Acid catalysis of the formation of the slow-folding species of RNase A: evidence that the reaction is proline isomerization. Proc Natl Acad Sci U S A 75:4764–4768. http://dx.doi.org/10.1073/pnas.75.10.4764.

3. Schmid FX, Buchner J, Kiefhaber T. 2005. Prolyl isomerization in protein folding: evidence for the existence of a family of distinct enzymes. Biochemistry 38:3316–3816. http://dx.doi.org/10.1021/bi05048a001.

4. Stein RL. 1993. Mechanism of enzymatic and nonenzymatic prolyl cis-trans isomerization. Adv Protein Chem 44:1–24. http://dx.doi.org/10.1016/S0091-6700(08)60562-8.

5. Park ST, Aldape RA, Futer O, DeCenzo MT, Livingston DJ. 1992. PPase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. J Biol Chem 267:3316–3324.

6. Schreiber SL. 1991. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283–287. http://dx.doi.org/10.1126/science.1702904.
Pathogenic FKBP12 Structures Suggest Self-Catalysis

26. Schreiber SL, Crabtree GR. 1995. Immunophilins, ligands and the control of signal transduction. Harvey Lect 91:99–114.

27. Kang CB, Hong Y, Dhe-Paganon S, Yoon HS. 2008. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 16:318–325. http://dx.doi.org/10.1159/000123041.

28. Hemenway CS, Heitman J. 1999. Calcineurin. Structure, function and inhibition. Cell Biochem Biophys 30:115–151. http://dx.doi.org/10.1007/BF02738787.

29. Im SH, Rao A. 2004. Activation and deactivation of gene expression by Ca\(^{2+}\)/calcineurin-NFAT-mediated signaling. Mol Cells 18:1–9.

30. Clipstone NA, Crabtree GR. 1992. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 357:695–697. http://dx.doi.org/10.1038/357695a0.

31. Steinbach WJ, Reedy JI, Cramer RA, Jr, Perfect JR, Heitman J. 2007. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5:418–430. http://dx.doi.org/10.1038/nrmicro1680.

32. O’Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O’Neill EA. 1992. FK-506 and CaA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357:692–694. http://dx.doi.org/10.1038/357692a0.

33. Galat A. 2013. Functional diversity and pharmacological profiles of the FKBP's and their complexes with small natural ligands. Cell Mol Life Sci 70:3243–3275. http://dx.doi.org/10.1007/s00018-012-1206-z.

34. Dornan J, Taylor P, Walkinshaw MD. 2003. Structures of immunophilins and their ligand complexes. Curr Top Med Chem 3:1392–1409. http://dx.doi.org/10.2174/1568026033451899.

35. Alag R, Balakrishna AM, Rajan S, Qureshi IA, Shin J, Lescar J, Grüber G, Yoon HS. 2013. Structural insights into substrate binding by PvFKBP35, a peptidylprolyl cis-trans isomerase from the human malarial parasite Plasmodium vivax. Eukaryot Cell 12:627–634. http://dx.doi.org/10.1128/EC.00016-13.

36. Ikura T, Ito N. 2007. Requirements for peptidyl-prolyl isomerization activity: a comprehensive mutational analysis of the substrate-binding cavity of FK506-binding protein 12. Protein Sci 16:2618–2625. http://dx.doi.org/10.1110/ps.073203707.

37. Ikura T, Kinoshita K, Ito N. 2008. A cavity with an appropriate size is the basis of the PPIase activity. Protein Eng Des Sel 21:83–89. http://dx.doi.org/10.1093/protein/gzm087.

38. Cardenas ME, Hemenway CS, Muir RS, Ye R, Fiorentino D, Heitman J. 1994. Immunophilins interact with calcineurin in the absence of endogenous immunosuppressive ligands. EMBO J 13:5944–5957.

39. Bastidas RJ, Shertz CA, Lee SC, Heitman J, Cardenas ME. 2012. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. Eukaryot Cell 11:270–281. http://dx.doi.org/10.1128/EC.00528-11.

40. Cruz MC, Blankenship J, Del Poeta M, Perfect JR, McCusker JH, Bennai YL, Cardenas ME, Heitman J. 2001. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother 45:3162–3170. http://dx.doi.org/10.1128/AAC.45.11.3162-3170.2001.

41. Futer O, DeCenzo MT, Aldape RA, Livingston DJ. 1995. FK506 binding protein mutational analysis. Defining the surface residue contributions to stability of the calcineurin co-complex. J Biol Chem 270:18935–18940. http://dx.doi.org/10.1074/jbc.270.32.18935.

42. Shou W, Aghdasi B, Armstrong DL, Guo Q, Bao S, Charing MJ, Mathews LM, Schneider MD, Hamilton SL, Matzuk MM. 1998. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391:489–492. http://dx.doi.org/10.1038/35146.

43. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Echols N, Headd JJ, Hung LW, Jain S, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D 66:213–221. http://dx.doi.org/10.1107/S0907444909052925.

44. Shimizu K, Keller NP. 2001. Genetic involvement of a cAMP-dependent protein kinase in a G protein signaling pathway regulating morphological and chemical transitions in Aspergillus nidulans. Genetics 157:591–600.

45. Falloon K, Juvvadi PR, Richards AD, Vargas-Muniz JV, Renshaw H, Steinbach WJ. 2015. Characterization of the Fkbp12-encoding genes in Aspergillus fumigatus. PLoS One 10:e0137869. http://dx.doi.org/10.1371/journal.pone.0137869.

46. Steinbach WJ, Cramer RA, Jr., Perfect BZ, Asfaw YG, Sauer TG, Najvar LL, Kirkpatrick WR, Patterson TF, Benjamin DK, Jr., Heitman J, Perfect JR. 2006. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell 5:1091–1103. http://dx.doi.org/10.1128/EC.00139-06.

47. Juvvadi PR, Fortwendel JR, Rogg LE, Burns KA, Randell SH, Steinbach WJ. 2011. Localization and activity of the calcineurin catalytic and regulatory subunit complex at the septum is essential for hyphal elongation and proper septation in Aspergillus fumigatus. Mol Microbiol 82:1235–1259. http://dx.doi.org/10.1111/j.1365-2958.2011.07886.x.